Product
Measles-rubella
1 clinical trial
1 indication
Indication
MalariaClinical trial
A Phase Ib Trial to Evaluate the Safety and Immunogenicity of R21/Matrix-M in a Single and Two Vial Presentation, With Different Immunisation Schedules, and When Co-Administered With EPI Vaccines in African ChildrenStatus: Active (not recruiting), Estimated PCD: 2025-05-01